Market Cap 367.39M
Revenue (ttm) 0.00
Net Income (ttm) -94.26M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 235,500
Avg Vol 274,958
Day's Range N/A - N/A
Shares Out 56.44M
Stochastic %K 10%
Beta 0.48
Analysts Strong Sell
Price Target $29.33

Company Profile

Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatm...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 349 1971
Fax: 617 273 2637
Address:
22 Boston Wharf Road, 10th floor, Boston, United States
Zackattack15xx
Zackattack15xx Oct. 16 at 6:48 PM
0 · Reply
JarvisFlow
JarvisFlow Oct. 16 at 10:48 AM
HC Wainwright & Co. updates rating for Astria Therapeutics ( $ATXS ) to Neutral.
0 · Reply
anachartanalyst
anachartanalyst Oct. 15 at 4:02 PM
$ATXS https://anachart.com/wp-content/uploads/ana_temp/1760544139_soc-img.jpg
0 · Reply
JarvisFlow
JarvisFlow Oct. 15 at 3:15 PM
Wedbush has adjusted their stance on Astria Therapeutics ( $ATXS ), setting the rating to Neutral with a target price of 28 → 13.
0 · Reply
ZacksResearch
ZacksResearch Oct. 15 at 2:40 PM
$ATXS rockets 37.1% on Tuesday after BioCryst buyout news! BioCryst is set to acquire Astria for a mix of cash and stock, representing a 53% premium, aiming to strengthen its HAE market position with Astria’s promising navenibart therapy. This strategic move is expected to enhance BioCryst’s growth over the next decade. Discover the full acquisition scoop here 👉 https://www.zacks.com/stock/news/2769310/astria-therapeutics-stock-rallies-37-on-700m-buyout-offer-from-bcrx?cid=sm-stocktwits-2-2769310-body-16167&ADID=SYND_STOCKTWITS_TWEET_2_2769310_BODY_16167
0 · Reply
ZacksResearch
ZacksResearch Oct. 15 at 1:30 PM
$ATXS surges 37% on $700M buyout deal BioCryst’s cash-and-stock offer strengthens its HAE treatment pipeline — a strategic grab that’s clearly energizing the market. Full merger details and what it means for investors 👉 https://www.zacks.com/stock/news/2769310/astria-therapeutics-stock-rallies-37-on-700m-buyout-offer-from-bcrx?cid=sm-stocktwits-2-2769310-teaser-16135&ADID=SYND_STOCKTWITS_TWEET_2_2769310_TEASER_16135
0 · Reply
PremarketAnalysis
PremarketAnalysis Oct. 15 at 11:56 AM
$ATXS SignalEngine: MM Infl (Neutral), Algo Vol 34%, Org Vol 70%, BRX 0% Algo Int: holding post-surge zone, awaiting secondary expansion Momentum Feed: https://premarketanalysis.com/#momentum=ATXS
0 · Reply
JarvisFlow
JarvisFlow Oct. 15 at 11:16 AM
JMP Securities has updated their rating for Astria Therapeutics ( $ATXS ) to Market Perform.
0 · Reply
StocktwitsNews
StocktwitsNews Oct. 15 at 3:18 AM
BioCryst Stock Tumbles On Astria Buyout, But Analysts Stay Bullish — Retail Cheers The Move As Long-Term Play $BCRX $ATXS https://stocktwits.com/news/equity/markets/bio-cryst-stock-tumbles-on-astria-buyout-but-analysts-stay-bullish-retail-cheers-long-term-play/ch6n1kVR3ZL
1 · Reply
TwongStocks
TwongStocks Oct. 14 at 9:02 PM
$ATXS ATXS shareholders will get $8.55 plus 0.59 shares of $BCRX for each share held. The buyout valuation of $13 is based on BCRX's 20-day VWAP as of Oct 8 ($7.54). $8.55 + (0.59 * $7.54) = $12.9986 With BCRX's closing at $6.42 today, that would put a value of $12.3378 for each ATXS share if the merger were to close today. $8.55 + (0.59 * $6.42) = $12.3378 The buyout currently represents a 6.27% premium to ATXS's closing price of $11.61. Will be interesting to see how BCRX's price fares until this transaction closes.
1 · Reply
Latest News on ATXS
BioCryst to buy Astria Therapeutics in $700 million deal

Oct 14, 2025, 7:35 AM EDT - 21 days ago

BioCryst to buy Astria Therapeutics in $700 million deal

BCRX


Astria Therapeutics: A High-Conviction Bet On HAE

Feb 17, 2025, 10:32 PM EST - 9 months ago

Astria Therapeutics: A High-Conviction Bet On HAE


Zackattack15xx
Zackattack15xx Oct. 16 at 6:48 PM
0 · Reply
JarvisFlow
JarvisFlow Oct. 16 at 10:48 AM
HC Wainwright & Co. updates rating for Astria Therapeutics ( $ATXS ) to Neutral.
0 · Reply
anachartanalyst
anachartanalyst Oct. 15 at 4:02 PM
$ATXS https://anachart.com/wp-content/uploads/ana_temp/1760544139_soc-img.jpg
0 · Reply
JarvisFlow
JarvisFlow Oct. 15 at 3:15 PM
Wedbush has adjusted their stance on Astria Therapeutics ( $ATXS ), setting the rating to Neutral with a target price of 28 → 13.
0 · Reply
ZacksResearch
ZacksResearch Oct. 15 at 2:40 PM
$ATXS rockets 37.1% on Tuesday after BioCryst buyout news! BioCryst is set to acquire Astria for a mix of cash and stock, representing a 53% premium, aiming to strengthen its HAE market position with Astria’s promising navenibart therapy. This strategic move is expected to enhance BioCryst’s growth over the next decade. Discover the full acquisition scoop here 👉 https://www.zacks.com/stock/news/2769310/astria-therapeutics-stock-rallies-37-on-700m-buyout-offer-from-bcrx?cid=sm-stocktwits-2-2769310-body-16167&ADID=SYND_STOCKTWITS_TWEET_2_2769310_BODY_16167
0 · Reply
ZacksResearch
ZacksResearch Oct. 15 at 1:30 PM
$ATXS surges 37% on $700M buyout deal BioCryst’s cash-and-stock offer strengthens its HAE treatment pipeline — a strategic grab that’s clearly energizing the market. Full merger details and what it means for investors 👉 https://www.zacks.com/stock/news/2769310/astria-therapeutics-stock-rallies-37-on-700m-buyout-offer-from-bcrx?cid=sm-stocktwits-2-2769310-teaser-16135&ADID=SYND_STOCKTWITS_TWEET_2_2769310_TEASER_16135
0 · Reply
PremarketAnalysis
PremarketAnalysis Oct. 15 at 11:56 AM
$ATXS SignalEngine: MM Infl (Neutral), Algo Vol 34%, Org Vol 70%, BRX 0% Algo Int: holding post-surge zone, awaiting secondary expansion Momentum Feed: https://premarketanalysis.com/#momentum=ATXS
0 · Reply
JarvisFlow
JarvisFlow Oct. 15 at 11:16 AM
JMP Securities has updated their rating for Astria Therapeutics ( $ATXS ) to Market Perform.
0 · Reply
StocktwitsNews
StocktwitsNews Oct. 15 at 3:18 AM
BioCryst Stock Tumbles On Astria Buyout, But Analysts Stay Bullish — Retail Cheers The Move As Long-Term Play $BCRX $ATXS https://stocktwits.com/news/equity/markets/bio-cryst-stock-tumbles-on-astria-buyout-but-analysts-stay-bullish-retail-cheers-long-term-play/ch6n1kVR3ZL
1 · Reply
TwongStocks
TwongStocks Oct. 14 at 9:02 PM
$ATXS ATXS shareholders will get $8.55 plus 0.59 shares of $BCRX for each share held. The buyout valuation of $13 is based on BCRX's 20-day VWAP as of Oct 8 ($7.54). $8.55 + (0.59 * $7.54) = $12.9986 With BCRX's closing at $6.42 today, that would put a value of $12.3378 for each ATXS share if the merger were to close today. $8.55 + (0.59 * $6.42) = $12.3378 The buyout currently represents a 6.27% premium to ATXS's closing price of $11.61. Will be interesting to see how BCRX's price fares until this transaction closes.
1 · Reply
RunnerSignals
RunnerSignals Oct. 14 at 8:59 PM
Biotech Bonanza Leads Today Action $ATXS getting acquired for $13/share $SSKN laser breakthrough $AKA fashion momentum $AREC mining the gains Meanwhile $BYND hits penny stock status https://stocksrunner.com/news/2025-10-14-top-movers-and-shakers-command-attention
0 · Reply
agamemnus
agamemnus Oct. 14 at 8:46 PM
$ATXS I guess it is off my watch list :(
0 · Reply
JarvisFlow
JarvisFlow Oct. 14 at 6:19 PM
Jefferies updates rating for Astria Therapeutics ( $ATXS ) to Hold, target set at 30 → 13.
1 · Reply
leosp11
leosp11 Oct. 14 at 4:38 PM
$ATXS the worst are the slow bleeder. I am out
1 · Reply
topstockalerts
topstockalerts Oct. 14 at 3:58 PM
Top Gainers PT2 $TMQ $NUAI $SSKN $ATXS $AREC
0 · Reply
Skinner12345
Skinner12345 Oct. 14 at 3:53 PM
$ATXS at least $13
0 · Reply
topstockalerts
topstockalerts Oct. 14 at 3:17 PM
Top Gainers PT2 $TMQ $SSKN $ATXS $AREC $JDZG
0 · Reply
Zackattack15xx
Zackattack15xx Oct. 14 at 2:07 PM
$ATXS what’s the pt on this ?
1 · Reply
topstockalerts
topstockalerts Oct. 14 at 1:45 PM
$ATXS strong watch for today..
0 · Reply
caprihunter
caprihunter Oct. 14 at 1:44 PM
0 · Reply
topstockalerts
topstockalerts Oct. 14 at 1:43 PM
$ATXS this setup continues to provide opportunities.. stay tuned!
0 · Reply
Webullbro
Webullbro Oct. 14 at 1:35 PM
0 · Reply